Enrolling Patients Soon for

Congenital Adrenal Hyperplasia Clinical Trials 2017

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may soon be eligible to participate in a Phase 2 clinical trial for a new, once-a-day therapy for CAH. To be notified when a site opens near you, sign up for our mailing list.

Learn More

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. Our mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”). We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.